5 Minutes
It starts as a niggling ache. Then the legs feel heavy. Simple tasks become a test of will. For roughly one in ten people who take statins, this is not an occasional nuisance but a persistent reason to stop a drug that otherwise protects the heart.
How a tiny gate can leak pain into muscle
New work from researchers at Columbia University and the University of Rochester points to a microscopic culprit: a calcium channel in muscle cells known as ryanodine receptor 1, or RyR1. The idea is almost cinematic. A gate that should be closed opens at the wrong time, calcium floods the muscle, and damage follows.
Statins lower harmful LDL cholesterol by blocking an enzyme the liver uses to make cholesterol. That action saves lives by reducing the risk of heart attacks and strokes. But drugs are rarely perfectly targeted. Some statins appear to interact with off target proteins, and RyR1 is one of them.
RyR1 lives on the sarcoplasmic reticulum, a reticulated membrane that envelops muscle fibers. When RyR1 opens, calcium pours into the cell and triggers contraction. That flow must be tightly regulated. If the gate stays open, cells are exposed to a harmful, sustained calcium signal that can activate destructive enzymes and weaken tissue.
Using cryo electron microscopy the team captured how simvastatin molecules sit against RyR1 in mouse tissue. Cryo electron microscopy freezes biological samples and images them with electron beams to reveal atomic details. The images suggest that simvastatin can stabilize RyR1 in a more open configuration, creating a chronic leak of calcium into muscle cells.
The downstream effects are familiar to clinicians. Patients report pain, tenderness, weakness and cramps. In rare but serious cases the damage can escalate to rhabdomyolysis, when muscle fibers break down and release proteins into the bloodstream that can harm the kidneys. Some patients develop autoimmune necrotizing myositis, where the immune system attacks muscle tissue.
People with preexisting RyR1 mutations are especially vulnerable. Those mutations can already predispose patients to malignant hyperthermia or diaphragm weakness. Add a statin that nudges the channel open and the consequences can be severe.
Scale matters. Around 40 million adults in the United States take statins and about 10 percent experience statin associated muscle symptoms, often abbreviated as SAMS. That number translates to millions of people worldwide who struggle with side effects and may stop treatment that lowers their cardiovascular risk.
Where this leads researchers
There are two practical paths forward. One is to redesign statins so they retain their liver focused cholesterol lowering but do not bind RyR1. That is a medicinal chemistry challenge, but an achievable one given modern drug design tools.
The second is pharmacological rescue. The team tested an experimental compound class called Rycals in mice. Rycals are designed to stabilize RyR channels and prevent pathological calcium leak. In statin tolerant and statin intolerant mouse models, treatment with Rycal molecules closed the leaky gates and prevented simvastatin induced weakness.
These results do not claim that RyR1 is responsible for every case of SAMS. The biology of muscle pain is multifactorial. But if even a fraction of statin induced muscle complaints arise from RyR1 mediated leaks, targeted interventions could help millions continue cardioprotective therapy safely.
Andrew Marks, a cardiologist at Columbia, who led the study, notes that the clinical impact is immediate: clinicians often face patients who refuse statins because of side effects. Understanding a mechanism offers concrete ways to screen and to treat. Screening could include genetic tests for RyR1 variants, while treatments could combine modified statins with Rycal like compounds when appropriate.
The study appears in the Journal of Clinical Investigation and builds on decades of work into both statin pharmacology and RyR biology. It also underscores how high resolution structural biology can illuminate side effects that were previously mysterious.
Expert Insight
Dr Emily Hart, a muscle physiologist at a major academic hospital, commented on the translational promise of the work: ‘This study connects structural detail to patient experience. We have long suspected that off target actions cause some statin intolerance. Seeing a plausible molecular mechanism means we can now test targeted therapies in clinical trials. That is the most hopeful step for patients who need their cholesterol controlled but cannot tolerate current medicines.’
Conclusion
Statins remain one of the most effective tools to reduce cardiovascular risk. Still, side effects drive many patients away. The discovery that statins can promote a calcium leak through RyR1 gives researchers a tangible target to fix. Whether through redesigned drugs, adjunctive Rycal treatments, or genetic screening, the goal is clear: keep the heart protected while preventing unnecessary muscle harm. For millions, that could mean the difference between stopping therapy and staying well.
Source: sciencealert
Comments
DaNix
Is this for real? Sounds plausible but 10% seems high. Any idea how they'll test this in ppl vs mice? Curious and a bit skeptical.
bioNix
Wow never thought a tiny channel could wreck legs... been on statins and the cramps were brutal. Hope they fix meds so ppl dont have to quit, fingers crossed.
Leave a Comment